The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.
February 17th 2025
Female dialysis patients had a greater risk of infection- and withdrawal-related mortality, while men were more likely to die from cardiovascular disease and cancer.
Clinical, Pathological Distinctions Provide Basis for Differentiating IgAN, IgAVN
February 7th 2024Findings from this retrospective study help address challenges in distinguishing immunoglobulin A nephropathy from immunoglobulin A vasculitis-associated nephritis, overcoming their shared pathogenetic features.
Home-Based Albuminuria Screening Cost-Effective for Preventing Kidney, Cardiovascular Events
February 6th 2024Findings highlight the potential benefits of implementing home-based screening for albuminuria in the general population to reduce the burden of kidney and cardiovascular diseases while maintaining cost-effectiveness.
Hydroxychloroquine, Leflunomide Improve Proteinuria, Renal Function in IgAN
February 5th 2024Hydroxychloroquine and leflunomide were found to be safe and effective for treating IgAN, with study results showing the use of both immunosuppressants in combination with a renin-angiotensin system inhibitor proved most effective in improving proteinuria and stabilizing renal function.
Endocrinology Month in Review: January 2024
January 31st 2024This endocrinology month in review spotlights FDA news, a pair of studies examining cardiovascular and renal risk reduction in type 2 diabetes, results from a subtrial examining testosterone’s effect on fracture risk, and 4 new episodes of diabetes dialgoue
eGFR Based on Creatinine, Cystatin C May Offer Better CKD Threshold for Older Adults
January 31st 2024Low eGFRcr-cys was more strongly and uniformly associated with adverse outcomes compared to low eGFRcr in an older patient population, highlighting the benefit of including cystatin C in GFR estimation.
Patients With Vitiligo, End-Stage Renal Disease Face Greater Risk of Infection
January 30th 2024Vitiligo was significantly associated with an increased risk of bacteremia, cellulitis, and herpes zoster and was more common among those with female sex, Black compared to White race, Hispanic ethnicity, hepatitis C infection, and tobacco use.
SGLT2i Use Linked to Lower Risk of Nephrolithiasis in Patients With Type 2 Diabetes
January 29th 2024Compared to glucagon-like peptide 1 receptor agonists and dipeptidyl peptidase 4 inhibitors, Use of sodium-glucose cotransporter 2 inhibitors was linked to a decreased risk of nephrolithiasis in patients with type 2 diabetes.
Automated AKI Alert Prompts Change of Care, Shows No Impact on Patient Outcomes
January 26th 2024Use of the electronic AKI alert system led to slight improvements in intervention rates and AKI diagnosis, although kidney function and patient-centered outcomes did not differ from patients receiving usual care.
72-Week Phase 2B ORIGIN Data Highlight Potential Benefit of Atacicept in IgA Nephropathy
January 25th 2024The 72-week open-label extension of the phase 2b ORIGIN trial reveals atacicept's potential as a disease-modifying treatment for IgA nephropathy, showing eGFR stabilization and improvements in key indicators
Patients with IgA Nephropathy May Not Be Receiving Optimal Supportive Care
January 24th 2024Results called attention to suboptimal blood pressure and proteinuria control as well as a lack of maximal RAASI dosing in a cohort of adult patients with IgAN from the Cure Glomerulonephropathy Network study.
Corticosteroids Induce Remission in Patients With IgA Nephropathy, Moderate Proteinuria
January 19th 2024Patients with IgAN and urine protein levels of 0.75–3.5 g/d treated with corticosteroids exhibited significantly greater overall and complete remission rates compared to those who received supportive care.
CBT-I, Trazodone Ineffective at Improving Insomnia for Patients on Hemodialysis
January 18th 2024Investigators observed no change in Insomnia Severity Index scores from baseline to weeks 7 and 25 with CBT-1, trazodone, or placebo, suggesting these insomnia treatment options are not effective for patients undergoing hemodialysis.
Clinical, Prognostic Factors Affecting Concurrent IgAN and Membranous Nephropathy Outcomes
January 15th 2024Results of the retrospective study suggested blood pressure, serum IgA, potassium, and segmental glomerulosclerosis may be predictive of the rapid progression of renal endpoints in patients with concurrent IgAN and membranous nephropathy.